Interesting to read this thread and comments in the context of yesterday's announcement about Sygenus results compared to morphine!
RGS is certainly on a very upwards trend when it comes to R&D, trials and product pipeline.
All combined, this strengthens the assumption that the company's valuation is grossly underestimated with its current SP.
RGS Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held